Condition: Pancreatic Ductal Adenocarcinoma (PDAC) · Sponsor: Institut Curie
Assessment of the relevance of a new medical imaging test, FAPI PET, which could detect progression or relapse earlier than other tests currently available. Ultimately, it could enable early forms of pancreatic cancer to be detected and used for screening. In addition to the usual examinations prescribed, FAPI PET scans will be repeated at several points in the treatment process. All study patients must first have been included in the Homing cohort (NCT 04363983, APHP promotion). Clinical characteristics, judgement criteria and results of biological or imaging examinations carried out as part of this cohort will be shared. Patient follow-up and participation in the study ends when conventional imaging (CT and MRI) shows disease progression, relapse or death.
This description comes directly from the study's public registry record.
Marie-Emmanuelle LEGRIER · 0033156245765 · drci.promotion@curie.fr
Sandra NESPOULOUS · 0033147111654 · drci.promotion@curie.fr
Always discuss trial participation with your own doctor first.
| Institut Curie -site Saint-Cloud | Saint-Cloud, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06659705